COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,669 Articles (22,913 medRxiv, 8,756 bioRxiv)

Most recent first Previous |  Page 828: Articles 8271-8280  | Next

In situ architecture and membrane fusion of SARS-CoV-2 Delta variant
Song, Y., Yao, H., Wu, N., Zhang, Z., Xu, J., Peng, C., Li, S., Kong, W., Chen, Y., Zhu, M., Wang, J., Shi, D., Zhao, C., Lu, X., Echavarria Galindo, M., Li, S.
10.1101/2022.05.13.491759 — Posted: 2022-05-13
A study protocol for a retrospective cohort study and interrupted time series analysis to assess the effect of the COVID-19 pandemic on major trauma presentations and patient outcomes in English hospitals.
Marincowitz, C., Bouamra, O., Coates, T., Kumar, D., Lockey, D., Mason, L., Newcombe, V., Thompson, J., Yates, D., Lecky, F.
10.1101/2022.05.10.22274804 — Posted: 2022-05-13
Delivery of Circular mRNA via Degradable Lipid Nanoparticles against SARS-COV-2 Delta Variant
Huang, K., Li, N., Li, Y., Zhu, J., Fan, Q., Yang, J., Gao, Y., Liu, Y., Hou, Q., Gao, S., Wei, K., Deng, C., Zuo, C., Sun, Z.
10.1101/2022.05.12.491597 — Posted: 2022-05-12
The SARS-CoV-2 Spike Protein Activates the Epidermal Growth Factor Receptor-Mediated Signaling
Palakkott, A., Alneyadi, A., Muhammad, K., Ali, E. H., Amiri, K., Ayoub, M. A., Iratni, R.
10.1101/2022.05.10.491351 — Posted: 2022-05-12
Biochemical Characterization of Emerging SARS-CoV-2 Nsp15 Endoribonuclease Variants
Wilson, I. M., Frazier, M. N., Li, J.-L. N., Randall, T. A., Stanley, R. E.
10.1101/2022.05.10.491349 — Posted: 2022-05-12
Low immune response after 1.5 years of primary SARS-CoV-2 infection and Covishield vaccination lead to SARS-CoV-2 reinfection
Shete, A. M., Patil, D. Y., Sahay, R. R., Sapkal, G. N., Deshpande, G. R., Yadav, P.
10.1101/2022.05.12.491584 — Posted: 2022-05-12
A Mathematical Model of the Within-Host Kinetics of SARS-CoV-2 Neutralizing Antibodies Following COVID-19 Vaccination
dePillis, L., Caffrey, R., Chen, G., Dela, M. D., Eldevik, L., McConnell, J., Shabahang, S., Varvel, S. A.
10.1101/2022.05.11.491557 — Posted: 2022-05-12
A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern
Yuan, M., Chen, X., Zhu, Y., Dong, X., Liu, Y., Qian, Z., Ye, L., Liu, P.
10.1101/2022.05.11.491588 — Posted: 2022-05-12
Effect on the conformations of spike protein of SARS-CoV-2 due to mutation
Mallick Gupta, A., Chakrabarti, J.
10.1101/2022.05.11.491583 — Posted: 2022-05-12
Detection Of SARS-CoV-2 Variants Of Concern In Wastewater Of Leuven, Belgium
Bloemen, M., Delang, L., Rector, A., Raymenants, J., Thibaut, J., Pussig, B., Fondu, L., Aertgeerts, B., Van Ranst, M., Van Geet, C., Arnout, J., Wollants, E.
10.1101/2022.05.12.22274823 — Posted: 2022-05-12

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).